4593   HEALIOS K. K.

04/09/2024 11:30	Joint Research Agreement with AND medical to Utilize Healios Technology and Culture Supernatant
04/04/2024 09:00	Healios Acquires Substantially All of the Assets of Athersys, Inc. Free and Clear of Liabilities, Becomes Sole Owner of MultiStem
02/22/2024 10:30	Notice Concerning Reduction of Capital Stock and Capital Reserves and Appropriation of Surplus
02/22/2024 10:30	Notice of the Nomination of Candidates for the HEALIOS K.K. Board of Directors
02/14/2024 15:00	FY2023 Financial Results (Material)
02/02/2024 12:30	Start of ARDS Clinical Trial in Japan
01/18/2024 10:30	Submission of ARDS Clinical Trial Notification in Japan
01/17/2024 18:00	Publication of JAMA Neurology Article on Clinical Trial for Ischemic Stroke in Japan
01/16/2024 12:30	Announcement of Letter of Intent on Joint Research for Utilization of Culture Supernatant
01/09/2024 15:00	Healios enters into Agreement to Serve as DIP Lender and Stalking Horse Purchaser to acquire substantially all of the assets of Athersys
12/27/2023 15:00	Announcement of Letter of Intent with Nobelpharma for the Development and Commercialization of HLCM051 for ARDS in Japan
12/22/2023 15:00	Announcement of Strategic Investment in Arktus Therapeutics Inc.
11/14/2023 15:00	FY2023 Q3 Financial Results
10/19/2023 15:40	Statement regarding delisting announced by Athersys
10/16/2023 15:10	Notice of Change in Use of Funds
10/11/2023 17:00	Obtaining a Global License for ARDS and Provision of Clinical Trial Product from Athersys, Inc.
10/11/2023 11:30	Athersys Announced Status of Interim Analysis of Clinical Trial for Ischemic Stroke in the U.S. and Europe
09/14/2023 11:30	Healios eNK Cell Research by Thomas Jefferson University in Metastatic Uveal Melanoma
08/28/2023 15:00	Publication of Academic Article on Clinical Trial for ARDS in Japan
08/14/2023 15:00	Healios Establishes Subsidiary for eNK Research and Development
08/14/2023 15:00	FY2023 Q2 Financial Results
07/11/2023 12:40	Healios and Saisei Ventures Enter into a Letter of Intent and Establish Subsidiary for eNK Research and Development
07/06/2023 17:45	Healios and Saisei Ventures Enter into a Letter of Intent and Establish Subsidiary for ARDS Treatment Development
07/05/2023 12:00	Use of 3D bioreactor-based manufacturing method produced product for ARDS clinical trial (HLCM051)
06/23/2023 09:05	Start of phase 1/2 study in RPE tear using RPE cells derived from allogeneic iPS cells (HLCR011)
05/25/2023 08:30	Submission of an investigational new drug application for RPE tear using RPE cells derived from allogenic iPS Cells (HLCR011)
05/18/2023 12:00	(Delayed) Saisei Ventures Selected as a Certified VC Fund Manager by AMED to Catalyze the Japanese Drug Development Ecosystem
05/12/2023 15:15	FY2023 Q1 Financial Results
04/26/2023 12:00	ONE-BRIDGE study results to be presented at the 63rd Annual Meeting of The Japanese Respiratory Society
04/20/2023 15:00	Healios UDC-derived otic neural progenitor cells demonstrate enhanced survival after transplantation into the cochlea: Northwestern University